Opinion|Videos|April 18, 2025
Population Outcomes and Return on Value With CGMs
Experts discuss the metrics used to evaluate continuous glucose monitoring (CGM)'s comprehensive return on investment, including both cost savings and quality measure performance, and identify which patient populations demonstrate the strongest combined benefits in costs, quality measures, and outcomes, along with how these groups are prioritized for CGM access.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What metrics do you use to evaluate CGM's comprehensive return on investment, including both cost savings and quality measure performance?
- Which patient populations demonstrate the strongest combined benefits in costs, quality measures, and outcomes, and how do you prioritize these groups for CGM access?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Ocrelizumab Leads to Lower Hospitalization Rates Compared to Rituximab in MS
2
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
3
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
4
The Changing Treatment Landscape of IPF and PPF: Toby Maher, MD, PhD
5
